Research programme: neuronal nicotinic receptor modulators - Abbvie

Drug Profile

Research programme: neuronal nicotinic receptor modulators - Abbvie

Alternative Names: NS-1738; NSD-683; NSD-686

Latest Information Update: 22 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroSearch
  • Developer Abbott Laboratories
  • Class
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cognition disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 02 Jan 2013 No development reported - Preclinical for Cognition disorders in USA (unspecified route)
  • 31 Mar 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top